TVM is a leading inter­na­tio­nal venture capi­tal firm focu­sed on investing
in life science inno­va­tions. TVM pursues a unique two-pron­ged stra­tegy, finan­cing inno­va­tive early-stage thera­peu­tics through a single asset company approach (Project-Focu­sed Company, PFC), that lever­a­ges the firm’s stra­te­gic rela­ti­onship with global phar­maceu­ti­cal firm, Eli Lilly and Company. TVM also invests in diffe­ren­tia­ted commer­cial-stage medi­cal tech­no­lo­gies and late clini­cal-stage therapeutics.